Literature DB >> 31115504

Identification of pathogenic genes and transcription factors in glaucoma.

Jie Feng1, Jing Xu1.   

Abstract

Glaucoma is a group of eye diseases characterized by alterations in the contour of the optic nerve head, with corresponding visual field defects and progressive loss of retinal ganglion cells. The present study aimed to identify the key genes and upstream regulators in glaucoma. To screen the pathogenic genes involved in glaucoma, an integrated analysis was performed by using the microarray datasets in glaucoma derived from the Gene Expression Omnibus (GEO) database. The functional annotation and potential pathways of differentially expressed genes (DEGs) were additionally examined by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. A glaucoma‑specific transcriptional regulatory network was constructed to identify crucial transcriptional factors that target the DEGs in glaucoma. From two GEO datasets, 1,935 DEGs (951 upregulated and 984 downregulated genes) between glaucoma and normal controls were identified. GO and KEGG analyses identified that 'eye development' [false discovery rate (FDR)=0.00415533] and 'visual perception' (FDR=0.00713283) were significantly enriched pathways for DEGs. The expression of lipocalin 2 (LCN2), monoamine oxidase A (MAOA), hemoglobin subunit β (HBB), paired box 6 (PAX6), fibronectin (FN1) and cAMP responsive element binding protein 1 (CREB1) were demonstrated to be involved in the pathogenesis of glaucoma. In conclusion, LCN2, MAOA, HBB, PAX6, FN1 and CREB1 may serve roles in glaucoma, regulated by PAX4, solute carrier family 22 member 1, hepatocyte nuclear factor 4 α and ELK1, ETS transcription factor. These data may contribute to the development of novel potential biomarkers, reveal the underlying pathogenesis and additionally identify novel therapeutic targets for glaucoma.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31115504     DOI: 10.3892/mmr.2019.10236

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  7 in total

Review 1.  Pupillary response to chromatic light stimuli as a possible biomarker at the early stage of glaucoma: a review.

Authors:  Carla Arévalo-López; Silvia Gleitze; Samuel Madariaga; Iván Plaza-Rosales
Journal:  Int Ophthalmol       Date:  2022-07-04       Impact factor: 2.031

2.  A ZFP42/MARK2 regulatory network reduces the damage of retinal ganglion cells in glaucoma: a study based on GEO dataset and in vitro experiments.

Authors:  Yuan Yin; Shuai Wu; Lingzhi Niu; Shiwei Huang
Journal:  Apoptosis       Date:  2022-09-21       Impact factor: 5.561

3.  Therapeutic Properties of Ayahuasca Components in Ischemia/Reperfusion Injury of the Eye.

Authors:  Anna Szilágyi; Barbara Takács; Réka Szekeres; Vera Tarjányi; Mariann Bombicz; Dániel Priksz; Attila Kovács; Béla Juhász; Ede Frecska; Zoltán Szilvássy; Balázs Varga
Journal:  Biomedicines       Date:  2022-04-26

4.  When Is a Control Not a Control? Reactive Microglia Occur Throughout the Control Contralateral Pathway of Retinal Ganglion Cell Projections in Experimental Glaucoma.

Authors:  James R Tribble; Eirini Kokkali; Amin Otmani; Flavia Plastino; Emma Lardner; Rupali Vohra; Miriam Kolko; Helder André; James E Morgan; Pete A Williams
Journal:  Transl Vis Sci Technol       Date:  2021-01-12       Impact factor: 3.283

5.  Investigation of Key Signaling Pathways Associating miR-204 and Common Retinopathies.

Authors:  Ahmad Bereimipour; Leila Satarian; Sara Taleahmad
Journal:  Biomed Res Int       Date:  2021-10-04       Impact factor: 3.411

6.  Screening of primary open-angle glaucoma diagnostic markers based on immune-related genes and immune infiltration.

Authors:  Lingge Suo; Wanwei Dai; Xuejiao Qin; Guanlin Li; Di Zhang; Tian Cheng; Taikang Yao; Chun Zhang
Journal:  BMC Genom Data       Date:  2022-08-24

7.  Proteomic Study of Aqueous Humor and Its Application in the Treatment of Neovascular Glaucoma.

Authors:  Mengxi Yu; Feng Xie; Xiang Liu; Haidan Sun; Zhengguang Guo; Xiaoyan Liu; Wei Li; Wei Sun; Ying Wang; Chengyan He
Journal:  Front Mol Biosci       Date:  2020-10-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.